Financial Statements and Supplementary Information for the years ended January 31, 2021 and January 31, 2020

Table of Contents

	<u>Page</u>
Independent Auditor's Report	1-2
Financial Statements	
Statement of Financial Position	3
Statement of Activities	4
Statement of Functional Expenses	5
Statement of Cash Flows	6
Notes to Financial Statements	7-17
Supplementary Information	
Independent Auditor's Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	18-19
Schedule of Expenditures of State Financial Assistance	20
Notes to Schedule of Expenditures of State Financial Assistance	21
Schedule of Findings and Questioned Costs	22

CONDON O'MEARA McGinty & DONNELLY LLP

Certified Public Accountants

One Battery Park Plaza New York, NY 10004-1405 Tel: (212) 661 - 7777

Fax: (212) 661 - 4010

Independent Auditor's Report

To the Board of Directors of The ALS Association – Greater NY Chapter

We have audited the accompanying financial statements of The ALS Association - Greater NY Chapter (the "Association") which comprise the statement of financial position as of January 31, 2021 and January 31, 2020 and the related statements of activities, functional expenses and cash flows for the years then ended and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free from material misstatement. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to on the previous page present fairly, in all material respects, the financial position of The ALS Association – Greater NY Chapter as of January 31, 2021 and January 31, 2020 and the results of its activities and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Supplementary information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying Schedule of Expenditures of State Financial Assistance, is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated August 9, 2021 on our consideration of the Association's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Association's internal control over financial reporting and compliance.

Carre Dilesas We City & Donnelly LLP

Statement of Financial Position

Assets

	Janu	ary 31
	2021	2020
Cash and cash equivalents	\$ 1,088,403	\$ 1,340,662
Investments, at fair value – designated	4,259,963	4,081,054
Due from National ALS Association	_	74,421
Grants receivable	496,991	477,882
Prepaid expenses	105,964	141,014
Leasehold improvements, office property		•
and equipment, net	70,239	107,463
Security deposit	52,788	52,788
Total assets	\$ 6,074,348	\$ 6,275,284
Liabilities and Net Assets		
Liabilities		
Accounts payable and accrued	\$ 38,740	\$ 27,842
Deferred rent	228,204	143,408
Total liabilities	<u>266,944</u>	171,250
Net assets		
Without donor restrictions		
Operating	1,066,746	1,883,396
Board-designated fund	4,259,963	4,081,054
Total without donor restrictions	5,326,709	5,964,450
With donor restrictions	480,695	139,584
Total net assets	5,807,404	6,104,034
Total liabilities and net assets	\$ 6,074,348	\$ 6,275,284

Statement of Activities

					Years Ende	Years Ended January 31				
			1707					2020		
	Witho	Without Donor Restr Board-	Restrictions			Withou	Without Donor Restrictions Board-	ctions		
	Operating	Designated Fund	Total	With Donor Restrictions	Total	Operating	Designated Fund	Total	With Donor Restrictions	Total
Public support and revenue Contributions Government grant – PPP Gross revenue from special events Total public support and revenue Less: Expenses from special events Net revenue from charitable activities	\$1,191,054 444,457 1,850,331 3,485,842 724,035 2,761,807	\$ 42,402 - - 42,402	\$1,233,456 444,457 1,850,331 3,528,244 724,035 2,804,209	\$ 496,991 - - 496,991 -	\$1,730,447 444,457 1,850,331 4,025,235 724,035 3,301,200	\$1,545,122 - 3,613,099 5,158,221 1,532,320 3,625,901		\$1,545,122 - 3,613,099 5,158,221 1,532,320 3,625,901	\$ 465,604 - - 465,604 - - - - - - - - - - - - - - - - - - -	\$2,010,726 - 3,613,099 5,623,825 1,532,320 4,091,505
Investment return and other Investment return Net assets released from restrictions Net revenue available for Association's mission	393 155,88 <u>5</u> 2,918,08 <u>5</u>	356,507	356,900 155,885 3,316,994	5 (155,885) 341,111	3.658.105	32,356 542,118 4,200,375	467,614	499,970 542,118 4,667,989	87 (542.118) (76,427)	500,057
Expenses Program services Research and grants Patient services and support Public awareness and education Advocacy Total program services	238,491 2,068,480 288,176 192,544 2,787,691	190,000 280,000 - - 470,000	428,491 2,348,480 288,176 192,544 3,257,691	1 1 1 1	428,491 2,348,480 288,176 192,544 3,257,691	624,839 2,593,552 322,085 196,188 3,736,664	350,000 370,000 - - 720,000	974,839 2,963,552 322,085 196,188 4,456,664	1 1 1 1	974,839 2,963,552 322,085 196,188 4,456,664
Supporting activities Fundraising General and administrative Total supporting activities Total expenses	409,995 287,049 697.044 3,484,735	470,000	409,995 287,049 697,044 3,954,735	1 1 1	409,995 287,049 697,044 3,954,735	373,656 301,540 675,196 4,411,860	720,000	373,656 301,540 675,196 5,131,860	1 1 1	373,656 301.540 675.196 5,131,860
Increase (decrease) in net assets before interfund transfer Interfund transfer Increase (decrease) in net assets	(566,650) (250,000) (816,650)	(71,091) 250,000 178,909	(637,741)	341,111	(296,630)	(211,485)	(252,386)	(463,871)	(76,427) 	(540,298)
Net assets, beginning of year Net assets, end of year	1,883,396	4,081,054	5,964,450 \$5,326,709	139,584 \$ 480,695	6,104,034 \$5,807,404	2,094,881 \$1,883,396	4,333,440 \$4,081,054	6,428,321 \$5,964,450	\$ 139,584	6,644,332 86,104,034

See notes to financial statements.

Statement of Functional Expenses

Year Ended January 31, 2021

			Program Services	es			Supporting Activities	rities	
	Research	Patient	Public				General		
	and	Services	Awareness and	7	F -7 - 5		and		Ē
	Grants	and Support	Education	Advocacy	I otal	Fundraising	Administrative	Total	Total
Expenses Contributions	4 778 701	€	÷	Ð	470 401	e	6	e	\$ 400 to
Program costs	1/1/0/1	829.313	54.759	· ·	884.072	, ,	, ,		\$ 428,491 884 072
Direct activity costs	,	•		35,415	35,415	91,141	93,554	184,695	220,110
Salaries and related costs	1	1,278,388	204,623	133,570	1,616,581	279,520	168,366	447,886	2,064,467
Allocated costs of rent, telephone, computers, supplies,		170 000	107.90	72.550	380 000	7000	007	700 07	000
equipment remains, and manned and anortization of Total expenses before depreciation and amortization	428,491	2,287,693	288,176	192.544	3.196.904	409,995	285.612	695,607	3 892 511
Depreciation and amortization	,	60,787			60.787		1 437	1 437	62 234
Totals	\$ 428,491	\$2,348,480	\$ 288,176	\$ 192,544	\$3,257,691	\$ 409,995	\$ 287,049	\$ 697,044	\$3,954,735
Percentage of total expenses									
2021	10.8%	59.4%	7.3%	4.9%	82.4%	10.4%	7.2%	17.6%	100.0%
				Year E	Year Ended January 31, 2020	1, 2020			
			Program Services				Supporting Activities	ities	
	Research	Patient	Public				General		
	and	Services	Awareness and				and		
	Grants	and Support	Education	Advocacy	Total	Fundraising	Administrative	Total	Total
Expenses									
Contributions	\$ 974,839	, 69	- \$	•	\$ 974,839		· ~		\$ 974,839
Program costs	•	1,292,144	88,841	44,691	1,425,676	•	ı	ı	1,425,676
Direct activity costs	•	•	1	ı	1	67,368	104,485	171,853	171,853
Salaries and related costs	1	1,378,118	202,917	131,799	1,712,834	266,463	170,183	436,646	2,149,480
Allocated costs of rent, telephone, computers, supplies,		t c			1	,	!	,	
equipment rentals, and maintenance Total exnenses before demeciation and amortization	974 839	205,970	30,327	19,698	4 369 344	39,825	25,435	65,260	5 042 102
Depreciation and amortization	10.5	87,320		- 10,100	87.320	000,010	1 437	1 437	2,042,103
Totals	\$ 974,839	\$2,963,552	\$ 322,085	\$ 196,188	\$4,456,664	\$ 373,656	\$ 301,540	\$ 675,196	\$5,131,860
Percentage of total expenses	7000	, or		ò		1		,	:
2020	19.0%	57.7%	6.3%	3.8%	86.8%	7.3%	2.9%	13.2%	100.0%

See notes to financial statements.

Statement of Cash Flows

	Years Ended January 31			
		2021	<u> </u>	2020
Cash flows from operating activities				
(Decrease) in net assets	\$	(296,630)	\$	(540,298)
Adjustments to reconcile (decrease) in net	•	(======================================	4	(5.10,250)
assets to net cash (used in) operating activities				
Depreciation and amortization		62,224		88,757
In-kind donations of medical equipment		(25,000)		(62,200)
Unrealized (gain) on investments		(162,616)		(297,145)
Realized (gain) on sale of investments		(74,192)		(76,578)
Donated stocks		(14,153)		(3,044)
Proceeds from donated stocks		14,174		2,990
Realized (gain) loss on sale of donated stocks		(21)		54
Changes in assets and liabilities				
(Increase) decrease in due from National ALS				
Association		74,421		(21,250)
(Increase) decrease in grants receivable		(19,109)		73,486
(Increase) decrease in prepaid expenses		35,050		(15,101)
Increase (decrease) in accounts payable and				
accrued		10,898		(387,418)
Increase in deferred rent		84,796		52,747
Net cash (used in) operating activities		(310,158)	_(1,185,000)
Cash flows from investing activities				
Purchase of investments		(161,295)		(123,130)
Proceeds from sale of investments		470,000		750,000
Net change in money market funds		(250,806)		(761)
Net cash provided by investing activities	•	57,899		626,109
Net (decrease) in cash and cash equivalents		(252,259)		(558,891)
Cash and cash equivalents, beginning of year		1,340,662	1	1,899,553
Cash and cash equivalents, end of year	<u>\$</u>	1,088,403	<u>\$ 1</u>	1,340,662

Notes to Financial Statements January 31, 2021 and January 31, 2020

Note 1 – Nature of charitable organization

The mission of The ALS Association – Greater New York Chapter (the "Association") is to discover treatments and a cure for ALS, and to serve, advocate for, and empower people affected by ALS to live their lives to the fullest.

Principal Activities

The Association provides a wide range of services for people with ALS and their families living in New York City, Long Island, Westchester, Hudson Valley, and Northern and Central New Jersey. The Association sponsors ten multidisciplinary clinics in the region, makes loan of medical equipment and assistive communication devices, holds patient education symposia and monthly support groups, conducts home visits, provides transportation to quarterly clinic appointments, and offers social work and referral services.

The Association supports the funding of cutting-edge research taking place across the world. From individual projects to global collaborations, we provide funding to experts in a variety of scientific focus areas critical to advancing the search for effective treatments and a cure. Since 1995, the Association has expended approximately \$14.4 million on ALS-specific basic science and translational research.

Through external relations, our website, and social media, the Association continually raises awareness about ALS and the search for a cure. On average, 17,000 viewers visit our website quarterly, a vital source of information for those battling ALS and people looking for the latest news about the disease. Our social media channels including Facebook, Twitter, and Instagram reach nearly 12,000 followers.

The Association is the largest and most influential national advocacy organization in the United States focused solely on ALS. Our goal is to educate the public as well as policy makers at the state and federal level, and to drive toward smart decisions about ALS – related to research, treatment, and access to care. At the federal level, The ALS Association has been instrumental in securing annual funding for the Department of Defense's ALS Research Program, National ALS Registry at the Centers for Disease Control, and the National Institutes of Health ALS Research Program. At the state level, The Association Greater New York Chapter continues to build relationships with the state legislatures to secure government funding for care services that directly benefits people with ALS and their families.

Note 2 – Summary of significant accounting policies

Net assets

Without donor restrictions

Net assets without donor restrictions consist of amounts that can be spent at the discretion of the Association. The net assets also include those funds that are designated for specific purposes by the Board of Directors.

Notes to Financial Statements (continued) January 31, 2021 and January 31, 2020

Note 2 – Summary of significant accounting policies (continued)

Net assets (continued)

Without donor restrictions (continued)

Board-designated

The Challenge Fund:

During the summer of 2014, the Association generated significant revenue from the ALS Ice Bucket Challenge, a highly successful fundraising activity. The Board established The Challenge Fund (the "Fund") with the revenue that was raised from that activity. The Fund enables the Association to expand the funding of important programs consistent with its mission. The Fund was initially financed with \$5,250,000 and the Board established a policy statement governing investment of the Fund for the stated purpose of supporting the Association's research and patient services programs. The Association's Board of Directors (the "Board") has approved a plan that allocates approximately 60% of the funds for research and 40% for patient care programs.

To date, the Challenge Fund distributions include:

Fiscal year 2015:

\$1,250,000 to support a new ALS research program at the New York Genome Center.

Fiscal year 2016:

Patient Services:

\$185,000 to support a new multidisciplinary ALS treatment clinic at Columbia University Medical Center.

\$15,000 to purchase durable medical and augmentative communication equipment for the patient equipment loan program.

Research:

\$350,000 to support the Genomic Translation for ALS Clinical Care (GTAC) research initiative at Columbia University Medical Center.

Notes to Financial Statements (continued) January 31, 2021 and January 31, 2020

Note 2 – Summary of significant accounting policies (continued)

Net assets (continued)

Without donor restrictions (continued)

Board-designated (continued)

The Challenge Fund: (continued)

Fiscal year 2017:

Patient Services:

\$250,000 to support services at ALS treatment centers.

Research:

\$350,000 to support year two funding of the Genomic Translation for ALS Clinical Care (GTAC) research initiative at Columbia University Medical Center.

Fiscal year 2018:

Patient Services

\$250,000 to support services at ALS treatment centers.

Research

\$350,000 to support the NY Genome Center's ALS Research Program at its Center for Genomics of Neurodegenerative Disease (Phatnani Lab).

Fiscal year 2019:

Patient Services

\$250,000 to support services at ALS treatment centers.

Research

\$350,000 to support the NY Genome Center's ALS Research Program at its Center for Genomics of Neurodegenerative Disease (Phatnani Lab).

\$50,000 to support the Milton Safenowitz Postdoctoral Fellowship Program.

Notes to Financial Statements (continued) January 31, 2021 and January 31, 2020

Note 2 – Summary of significant accounting policies (continued)

Net assets (continued)

Without donor restrictions (continued)

Board-designated (continued)

The Challenge Fund: (continued)

Fiscal year 2020:

Patient Services

\$250,000 to support services at ALS treatment centers.

Research

\$300,000 to support the NY Genome Center's ALS Research Program at its Center for Genomics of Neurodegenerative Disease (Phatnani Lab).

\$100,000 to support the Milton Safenowitz Postdoctoral Fellowship Program.

Fiscal year 2021:

Patient Services

\$210,000 to support services at ALS treatment centers.

Research

\$190,000 to support the Milton Safenowitz Postdoctoral Fellowship Program.

The Ramey Fund:

Initially financed during fiscal year 2016 with \$1 million from a generous bequest from the Estate of Macaria Ramey, the Fund was established to support the Association's patient services programs. In fiscal year 2017, \$668,500 in additional distributions received from the Estate were added to the Ramey Fund.

During the 2019 fiscal year, the Board of Directors approved a grant of \$70,000 to support services at ALS treatment centers.

During the 2020 fiscal year, the Board of Directors approved a grant of \$70,000 to support services at ALS treatment centers, as well as \$30,000 to purchase equipment for the Association's Equipment Loan Program for patients.

During the 2021 fiscal year, the Board of Directors approved a grant of \$70,000 to support services at ALS treatment centers.

Notes to Financial Statements (continued) January 31, 2021 and January 31, 2020

Note 2 – Summary of significant accounting policies (continued)

Net assets (continued)

Without donor restrictions (continued)

Board-designated (continued)

Capital Management Fund:

Per an October 6, 2016 Board Resolution, the Association established the Capital Management Fund in accordance with its Investment Policy. Initially financed during fiscal year 2017 with \$500,000 in savings account reserves, the Capital Management Fund was established in order to responsibly invest the Association's assets but still be able to access funds in order to be able to take advantage of important research and patient services program funding opportunities when they arise.

During the 2021 fiscal year, the Board of Directors approved a transfer in the amount of \$250,000 from the Association's operating account to the Capital Management Fund in order to take advantage of the investment account's more favorable rate of return. Additionally, a bequest donation in the amount of \$42,402, was also added to the Capital Management Fund during the 2021 fiscal year.

With donor restrictions

Temporarily restricted revenue represents expendable gifts and grants, which are restricted by the donor or are to be made available in future periods. As the restrictions are satisfied, net assets with donor restrictions will be reclassified to net assets without donor restrictions and reported in the financial statement as net assets released from restrictions. The Association's policy is to record, as net assets without donor restrictions revenue, contributions when donor-imposed restrictions are met in the same year that the contributions are received. At January 31, 2021, the balance in net assets with donor restrictions will be used to fund the programs described in note 1.

Cash equivalents

The Association considers all highly liquid investments purchased, including money market accounts, with a maturity of three months or less to be cash equivalents.

Investments

The fair value of the investments is based on publicly quoted prices. Interest, dividends, realized and unrealized gains and losses on the investments are included in investment return in the statement of activities.

Notes to Financial Statements (continued) January 31, 2021 and January 31, 2020

Note 2 – Summary of significant accounting policies (continued)

Fair value measurements

For assets measured at fair value on a recurring basis as of January 31, 2021 and January 31, 2020, accounting principles generally accepted in the United States of America require quantitative disclosures about the fair value measurements separately for each major class of assets. The Association's investments have all been classified in the highest level of hierarchy (Level 1). Their quoted prices are in active markets for identical assets.

Allowance for doubtful accounts

As of January 31, 2021 and January 31, 2020, the Association deems its grants receivable to be collectible and, therefore, has not provided for an allowance for possibly uncollectible amounts. Such estimate is based on management's experience, the aging of the receivables, subsequent receipts and economic conditions.

Leasehold improvements, office property and equipment

The Association capitalizes as leasehold improvements, office property and equipment expenditures for assets above a nominal amount with an estimated useful life greater than one year. Expenditures for leasehold improvements, office property and equipment are capitalized at cost or, for donated assets, fair value at the time of donation. Depreciation and amortization are provided on a straight-line basis over the estimated useful lives of the related assets.

Contributions, donations and bequests

Contributions are recognized as revenue in the period in which they are received or pledged. Bequests are recognized at the time the Association's right to them is established by the Court and the proceeds are subject to reasonable estimation. Donations of medical equipment or other long-lived assets are classified as net assets without donor restrictions, and restrictions on the use of cash donations for the purchase thereof are considered met when the assets are purchased.

Government grants

Government grants are recorded as revenues to the extent that expenses have been incurred for the purposes specified by the grantors. Revenue from government agencies are subject to audit by the agencies. No provision for any disallowance is reflected in the financial statements, since management does not anticipate any material adjustments.

Allocation of functional expenses

The cost of providing the various programs has been summarized on a functional basis. Accordingly, certain costs have been allocated among programs and supporting services benefitted. Natural expenses attributable to more than one functional expense category are allocated using a variety of cost allocation techniques primarily consisting of salary and wages and time and effort reporting.

Notes to Financial Statements (continued) January 31, 2021 and January 31, 2020

Note 2 – Summary of significant accounting policies (continued)

Concentrations of credit risk

The Association's financial instruments that are potentially exposed to concentrations of credit risk consist primarily of cash, cash equivalents, investments and receivables. The Association places its cash and cash equivalents with what it believes to be quality financial institutions. At times during the year, cash balances may exceed the FDIC insurance limit; however, the Association has not experienced any losses on these accounts to date. Investments are exposed to various risks such as interest rate, market volatility, liquidity and credit. Due to the level of uncertainty related to the foregoing risks, it is reasonably possible that changes in these risks could materially affect the fair value of the investments reported in the statement of financial position at January 31, 2021. The Association routinely assesses the financial strength of its cash, cash equivalents and investment portfolio and monitors its receivables on an ongoing basis. Accordingly, the Association believes no significant concentrations of credit risk exist with respect to its cash, cash equivalents, investments and receivables.

Use of estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Risks and uncertainties

On March 13, 2020, a national emergency was declared due to extraordinary circumstances resulting from the coronavirus. The economic impact of the coronavirus on the Association's future financial operations is not readily determinable.

Subsequent events

The Association has evaluated events and transactions for potential recognition or disclosure through August 9, 2021, which is the date the financial statements were available to be issued.

Note 3 – Liquidity and availability of financial assets

The following is a summary of the Association's financial assets as of January 31, 2021 and January 31, 2020 available to meet cash needs for general expenditures within one year of the statement of financial position date:

	2021	 2020
Cash and cash equivalents	\$ 1,088,403	\$ 1,340,662
Due from National ALS Association	-	74,421
Grants receivables	496,991	477,882
Total financial assets as of year end	\$ 1,585,394	\$ 1,892,965

Notes to Financial Statements (continued) January 31, 2021 and January 31, 2020

Note 3 – Liquidity and availability of financial assets (continued)

As part of the Association's liquidity management, it has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. In addition, the Association invests cash in excess of daily requirements in short-term investments. The Association's Board-designated endowment assets total \$4,259,963 at January 31, 2021. Although the Association does not intend to spend from its Board-designated endowment other than amounts appropriated for general expenditures as part of its annual budget approval and appropriation process, amounts from its Board-designated funds could be made available, if necessary.

Note 4 – Investments

At January 31, 2021 and January 31, 2020, investments consist of the following:

	2	2021	2	020
	Cost	Fair Value	Cost	Fair Value
Money market funds	\$ 288,224	\$ 288,224	\$ 37,418	\$ 37,418
Mutual funds				
Vanguard Life Strategy				
Conservative Growth				
Investor Fund	1,773,979	2,126,975	1,869,539	2,121,584
Vanguard Life Strategy				
Income Fund	1,624,178	1,844,764	<u>1,763,131</u>	_1,922,052
Total mutual funds	3,398,157	3,971,739	3,632,670	4,043,636
Total investments	<u>\$3,686,381</u>	<u>\$4,259,963</u>	<u>\$3,670,088</u>	<u>\$4,081,054</u>

The investment return for the years ended January 31, 2021 and January 31, 2020 are as follows:

	2021	2020
Interest and dividends	\$ 120,076	\$ 126,388
Unrealized gain (loss)	162,616	297,145
Realized gain on sale of investments	74,192	76,578
Realized (loss) on sale of donated stocks	21	(54)
Investment return	\$ 356,905	\$ 500,057

Note 5 – Grants receivable

Grants receivable at January 31, 2021 are expected to be collected during the 2022 fiscal year.

Notes to Financial Statements (continued) January 31, 2021 and January 31, 2020

Note 6 - Leasehold improvements, office property and equipment

A summary of leasehold improvements, office property, equipment and accumulated depreciation and amortization as of January 31, 2021 and January 31, 2020 is as follows:

	2021	2020
Medical equipment	\$1,259,296	\$1,234,296
Leasehold improvements	25,344	25,344
Office equipment	20,481	20,481
Furniture and fixtures	25,084	25,084
Sub-total	1,330,205	1,305,205
Less: Accumulated depreciation and		
amortization	1,259,966	1,197,742
Total	\$ 70,239	\$ 107,463

Note 7 – Analysis of special events

•			Assoc	iation		
	Sports	<u>Dinner</u>	Sponsore	d Events	To	otal
	2021	2020	2021	2020	2021	2020
Gross revenue Less expenses	\$ 386,062 	\$ 690,030 410,570	\$1,464,269 576,802	\$2,923,069 	\$1,850,331 724,035	\$3,613,099 1,532,320
Net revenue from special events	\$ 238,829	\$ 279,460	<u>\$ 887,467</u>	\$1,801,319	\$1,126,296	\$2,080,779

Note 8 – Revenue sharing

Revenue sharing to the National ALS Association for the 2021 and 2020 fiscal years totaled \$291,363 and \$280,537, respectively, which was allocated to program services and support activity based on the National ALS Association's current revenue sharing plan agreement.

Note 9 - Paycheck protection program loan

2020 PPP loan

The Association applied for and in May 2020, received \$444,457 under the Paycheck Protection Program ("PPP") which is a business loan program established under the Coronavirus Aid, Relief, and Economic Security Act. The Association expended the full amount of the loan proceeds on purposes consistent with the PPP and maintained its payroll levels. The Association has, therefore, qualified for full forgiveness of the loan and accrued interest. For the year ended January 31, 2021, the Association elected to record the loan proceeds as a loan until forgiveness is authorized. On November 12, 2020, the loan and accrued interest was forgiven in full and the Association recorded the proceeds as a government grant on the 2021 statement of activities.

Notes to Financial Statements (continued) January 31, 2021 and January 31, 2020

Note 9 - Paycheck protection program loan (continued)

2021 PPP loan

The Association applied for and in February 2021, received \$445,767 under the Paycheck Protection Program under terms similar to the first PPP loan.

Note 10 - Lease agreement

During 2008, the Association entered into a lease agreement for office space. During December 2017, the Association modified its lease agreement, to acquire additional space and to extend the term of the lease effective May 2018 until June 2028.

Occupancy expense for the 2021 and 2020 fiscal years totaled \$344,970 and \$344,651, respectively.

Effective February 1, 2018, the base rental expense is being recognized on a straight-line basis over the life of the lease rather than in accordance with the actual lease payments. The difference between rent expense incurred by the Association on an accrual basis and the rent actually paid is reported as deferred rent liability in the statement of financial position.

At January 31, 2021 future minimum lease payments under the modified agreement are as follows:

Fiscal Year		Amount		
2022	\$	297,444		
2023		304,875		
2024		312,495		
2025		320,307		
2026		328,320		
2027 and thereafter		827,516		
Total	\$ 2	2,390,957		

Note 11 – Net assets with donor restrictions

Statutory law

The Association follows New York State Not-for-Profit Corporation Law (N-PCL) when adhering to donor-restricted contributions.

Notes to Financial Statements (continued) January 31, 2021 and January 31, 2020

Note 11 – Net assets with donor restrictions (continued)

Statutory law (continued)

Net assets with temporary donor restrictions are available for the following purposes as of January 31, 2021 and January 31, 2020:

		2021					
<u>Purpose</u>	Balance at January 31, 2020	Support and Other	Released from Restrictions	Balance at January 31, 2021			
Research Patient services Time restricted	\$ 12,146 39,726 87,712	\$ - 5 <u>496,991</u>	\$ - (10,000) <u>(145,885</u>)	\$ 12,146 29,731 438,818			
Total	<u>\$ 139,584</u>	\$ 496,996	<u>\$(155,885)</u>	\$ 480,695			
		2020					
<u>Purpose</u>	Balance at January 31, 2019	Support and Other	Released from Restrictions	Balance at January 31, 2020			
Research Patient services Time restricted	\$ 12,146 48,639 	\$ - 87 <u>465,604</u>	\$ - (9,000) <u>(533,118</u>)	\$ 12,146 39,726 87,712			
Total	\$ 216,011	\$ 465,691	\$(542,118)	\$ 139,584			

Note 12 – Retirement plan

The Association has a SIMPLE IRA where employees can contribute a portion of their salary not to exceed limits established by the Internal Revenue Code. The Association matches employee contributions up to 3% of the employee's compensation. Expense associated with this plan for the 2021 and 2020 fiscal years totaled \$43,273 and \$48,848, respectively.

Note 13 – Tax-exempt status

The Association has been classified by the Internal Revenue Service ("IRS") as a publicly supported organization classified under Section 170 (b)(1)(A)(vi) and 509(a)(1) of the Internal Revenue Code (the "Code") and that it is exempt from Federal income taxes under Section 501(c)(3) of the Code. In addition, the Association has been determined by the IRS to be a publicly supported organization and not a private foundation under the meaning of Section 509(a) of the Code, therefore contributions qualify for the maximum charitable deduction by donors under IRC Section 170 (b)(1)(A)(vi).

Independent Auditor's Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards

Condon O'Meara McGinty & Donnelly llp

Certified Public Accountants

One Battery Park Plaza New York, NY 10004-1405 Tel: (212) 661 - 7777 Fax: (212) 661 - 4010

To the Board of Directors of The ALS Association – Greater NY Chapter

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of The ALS Association – Greater NY Chapter (the "Association") which comprise the statement of financial position as of January 31, 2021 and the related statements of activities, functional expenses and cash flows for the year then ended and the related notes to the financial statements, and have issued our report thereon dated August 9, 2021.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Association's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Association's internal control. Accordingly, we do not express an opinion on the effectiveness of the Association's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Association's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Association's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Association's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Carre Drilesas We Crity & Donnelly LLP

Schedule of Expenditures of State Financial Assistance For the Year Ended January 31, 2021

State Grantor/Program Title	Grant <u>Number</u>	Grant Award <u>Period</u>	Total <u>Expenditures</u>
State of New Jersey		7/1/2020-	
Department of Health	DFHS18ALS002	1/1/2021	\$157,378

Notes to Schedule of Expenditures of State Financial Assistance For the Year Ended January 31, 2021

1. General information

The accompanying schedule of expenditures of state financial assistance presents the activities in the state program of The ALS Association – Greater New York Chapter (the "Association"). The state financial assistance received directly from the state agency is included on the schedule.

2. Basis of accounting

The accompanying schedule of expenditures of state financial assistance is presented using the accrual basis of accounting. The amounts reported in this schedule as expenditures may differ from certain financial reports submitted to the state funding agency due to those reports being submitted on either a cash or modified accrual basis of accounting.

3. Indirect cost rate

The Association did not use an indirect cost rate. All costs were direct payroll costs.

Schedule of Findings and Questioned Costs For the Year Ended January 31, 2021

Section I – Summary of Auditor's Results

Financial Statements

Type of auditor's report issued:	<u>Unmodified</u>		
Internal control over financial reporting:			
Material weakness(es) identified?	Yes	\checkmark	No
Significant deficiency(ies) identified that are			
not considered to be material weakness(es)?	Yes		None noted
Noncompliance material to financial statements noted?	Yes		No